Wong Suet Ping, Argyros Orestis, Harbottle Richard P
Leukocyte Biology Section, National Heart & Lung Institute, Imperial College London, London, UK.
Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Adv Genet. 2015;89:113-152. doi: 10.1016/bs.adgen.2014.11.002. Epub 2014 Dec 18.
DNA vectors have the potential to become powerful medical tools for treatment of human disease. The human body has, however, developed a range of defensive strategies to detect and silence foreign or misplaced DNA, which is more typically encountered during infection or chromosomal damage. A clinically relevant human gene therapy vector must overcome or avoid these protections whilst delivering sustained levels of therapeutic gene product without compromising the vitality of the recipient host. Many non-viral DNA vectors trigger these defense mechanisms and are subsequently destroyed or rendered silent. Thus, without modification or considered design, the clinical utility of a typical DNA vector is fundamentally limited due to the transient nature of its transgene expression. The development of safe and persistently expressing DNA vectors is a crucial prerequisite for its successful clinical application and subsequently remains, therefore, one of the main strategic tasks of non-viral gene therapy research. In this chapter we will describe our current understanding of the mechanisms that can destroy or silence DNA vectors and discuss strategies, which have been utilized to improve their sustenance and the level and duration of their transgene expression.
DNA载体有潜力成为治疗人类疾病的强大医学工具。然而,人体已经发展出一系列防御策略来检测并使外来或错位的DNA沉默,这种情况在感染或染色体损伤期间更为常见。一种具有临床相关性的人类基因治疗载体必须克服或避开这些保护机制,同时持续提供治疗性基因产物,且不损害受体宿主的活力。许多非病毒DNA载体触发这些防御机制,随后被破坏或沉默。因此,未经修饰或未经深思熟虑的设计,典型DNA载体的临床效用因其转基因表达的短暂性而从根本上受到限制。开发安全且能持续表达的DNA载体是其成功临床应用的关键先决条件,因此仍然是非病毒基因治疗研究的主要战略任务之一。在本章中,我们将描述我们目前对可破坏或沉默DNA载体的机制的理解,并讨论已被用于提高其持久性以及转基因表达水平和持续时间的策略。